Home » Topics » BioWorld Science

BioWorld Science
RSS

Sichuan Haisco Pharmaceutical patents JAK3 inhibitors

April 4, 2022

AIMer RNA base editing oligonucleotides edit ACTB transcript in the liver of nonhuman primates

April 4, 2022

New hederagenin derivatives display multidrug resistance reversal in tumors

April 4, 2022

AZD-9574: a selective PARP1 inhibitor suitable for cancer treatment

April 4, 2022

Novel TLR4 murine model to study dermal sensitization by nickel salts

April 4, 2022

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

April 1, 2022

Humanized mouse model to asses acute toxicity of immune drug treatments

April 1, 2022

New orthotopic xenograft breast cancer murine models developed

April 1, 2022

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

April 1, 2022

Telomere to telomere, the human genome is done

April 1, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...